Lentiviral human ATPAF2 sgRNA gene knockout kit

Lentiviral human ATPAF2 sgRNA gene knockout kit

Catalog Number:
CGKK546542FEN
Mfr. No.:
HKO-610768
Price:
$878
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Kit Components: Lentiviral particles or plasmids for a set of three sgRNAs, and a pair of Indel screening PCR primers

          sgRNA lentiviral particle information
          • Functional titer: 1x10^8 TU/ml
          • Titration method: counting puromycin resistant cell clones
          • Purity: In vivo grade
          • Pseudotype: VSVG
          • Storage buffer: LentiShield™ lentivirus storage buffer
          • Storage: condition -80°C
          • Availability: 3-5 weeks

          sgRNA lentiviral plasmid information
          • Promoter for target sgRNA: U6
          • Mammalian selection: puromycin
          • Promoter for mammalian selection gene: EF1a
          • E.coli selection: Amp
          • Storage condition: -20°C
          • Availability: 1-2 weeks

          Please contact us at for specific academic pricing.

          Target Information

          Target Name
          Human ATPAF2
          About Target
          Gene symbol: ATPAF2
          Synonyms: ATP12 ATP12p LP3663 MC5DN1
          Species: HUMAN
          Gene ID: 91647
          Summary: This gene encodes an assembly factor for the F(1) component of the mitochondrial ATP synthase. This protein binds specifically to the F1 alpha subunit and is thought to prevent this subunit from forming nonproductive homooligomers during enzyme assembly. This gene is located within the Smith-Magenis syndrome region on chromosome 17. An alternatively spliced transcript variant has been described, but its biological validity has not been determined. [provided by RefSeq, Jul 2008].
          NM numbers targeted (Accession number:Exon:CDS Fragment): NM_145691:3:3
      • Properties
        • * For Research Use Only.

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.